Abstract: A chain is provided which includes a plurality of interconnected chain-links. At least one chain-link of the chain has a braided core which includes a first primary strand having polymeric elongated elements having a tenacity of at least 1.0 N/tex. The braided core is braided from at least 2 consecutive turns of the primary strand. Also disclosed is a braided endless shaped element suitable as chain-link for the chain as well as a chain which has a tenacity (Ten) in N/Tex and a combined titer of the 2 legs of the chain-link having polymeric elongated elements (T) in MTex satisfying the relationship of Ten?0.50*T?0.05.

Abstract: This invention relates to a method for preparing a composition having a melt viscosity of between 160 Pas and 400 Pas, as determined according to ISO-11443-2014 at 270° C. and a shear rate of 265 l/s, and a volume resistivity of at most 105 Ohm·cm, measured according to ASTM D257 on an injection molded test sample of 3 mm thickness and a diameter of 50 mm and coated with a gold layer on an upper and lower surface and, as well as the composition itself and painted parts comprising the composition.

Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.

Abstract: The present invention is related to a new metal powder catalytic system (catalyst), its production and its use in hydrogenation processes.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The invention relates to an improved process for the manufacture of nano-sized organic UV absorbers having a mean particle size distribution (Dv50) determined by light scattering of less than 200 nm.

Abstract: The invention relates to a method for manufacturing a composite sheet comprising high performance polyethylene fibres and a polymeric resin comprising the steps of assembling HPPE fibres to a sheet, applying an aqueous suspension of a polymeric resin to the HPPE fibres, partially drying the aqueous suspension, optionally applying a temperature and/or a pressure treatment to the composite sheet wherein the polymeric resin is a homopolymer or copolymer of ethylene and/or propylene. The invention further relates to composite sheets obtainable by said method and articles comprising the composite sheet such as helmets, radomes or a tarpaulins.

Abstract: The present invention is based on the advantageous use of single-stranded oligonucleotides in the in vivo (within a cell) assembly of double-stranded oligonucleotides into a single double-stranded nucleic acid construct. The present invention relates to the use of at least a first and a second single-stranded oligonucleotide in the assembly within a cell of at least two double-stranded nucleic acid molecules into a single double-stranded nucleic acid construct of pre-determined sequence, wherein the first and second single-stranded oligonucleotide are essentially complementary to each other.

Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR-CAS system for a lipolytic yeast host cell.

Abstract: The invention relates to an optimized seed train expansion process.

Abstract: The present invention relates to a process for the production of ?-springene of formula (I) wherein a compound of formula (II) is heated in the presence of a catalyst.

Abstract: The present invention relates to a composition comprising one or more steviol glycosides which composition comprises kaurenoic acid in an amount of no more than 150 ppm. The invention also relates to a method for preparing a steviol glycoside composition, which method comprises: providing a steviol glycoside composition; combining the steviol glycoside composition with a solvent to form a steviol glycoside solution; and crystallizing a steviol glycoside composition from the steviol glycoside solution, wherein the crystallization is carried out at pH7.0 or below. The invention also relates to a method for reducing the kaurenoic acid content of a steviol glycoside composition, which method comprises: providing a steviol glycoside composition which comprises kaurenoic acid; combining the steviol glycoside composition with a solvent to form a steviol glycoside solution; and crystallizing a steviol glycoside composition from the steviol glycoside solution, wherein the crystallization is carried out at pH7.

Abstract: The present invention relates a process for the recovery of one or more steviol glycosides from a steviol glycoside-containing fermentation broth, which method comprises (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) providing an adsorbent resin; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least a portion of the one or more steviol glycosides from the non-steviol glycoside components, thereby to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides. The invention also relates to a purified steviol glycoside composition prepared using such a process.

Abstract: The present invention relates to a process for making high-strength polylactic acid elongated object comprising the steps of making a solution of polylactic acid in a solvent at a concentration of 5 to 50 mass %; spinning the solution through a spinplate comprising at least 1 spinhole to form a fluid elongated object; cooling the fluid elongated object with a cooling medium to form a solvent-containing gel elongated object; removing at least partly the solvent from the gel elongated object to form a solid elongated object; and drawing the elongated object while applying a draw ratio of at least 2, to form a high strength PLA elongated object, characterized in that the cooling medium has a temperature Tq of less than 0° C. The present invention also relates to gel-spun elongated objects comprising PLA with an IV in the range of 4-40 dl/g, and having a tenacity in N/tex such that Ten?0.146*IV, as well as gel-spun elongated object having a tenacity and a filament titer in tex (t) such that Ten?1.40*t ?0.3.

Abstract: The present invention relates a polypeptide having kaurenoic acid 13-hydroxylase activity, which polypeptide comprises an amino acid sequence which, when aligned with a kaurenoic acid 13-hydroxylase comprising the sequence set out in SEQ ID NO: 1 or SEQ ID NO: 3, comprises at least one substitution of an amino acid corresponding to any of amino acids at positions 136, 248, 336 or 403, said positions being defined with reference to SEQ ID NO: 1 or SEQ ID NO: 3 and wherein the polypeptide has one or more modified properties as compared with a reference polypeptide having kaurenoic acid 13-hydroxylase activity. A polypeptide of the invention may be used in a recombinant host for the production of steviol or a steviol glycoside.

Abstract: The present invention relates to a method for the enzymatic reduction of cystine to cysteine comprising contacting cystine with a reduction solution comprising: (i) an active glutathione reductase (EC1.8.1.7); (ii) a cofactor; and (iii) glutathione; and recovering a cysteine comprising composition, wherein the reduction solution has a pH of at least 6 during contacting with cystine.

Abstract: A system for providing improved engineered-composite materials, equipment, and manufacturing processes.

Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

Abstract: The present invention relates to a host cell which is capable of producing a dicarboxylic acid and which comprises at least one genetic modification in its genome resulting in the deficiency of at least one enzymatic step catalysing the oxidation of a cofactor. The invention also relates to a process for producing a dicarboxylic acid, which method comprises fermenting such a host cell in a suitable fermentation medium and producing the dicarboxylic acid.